dendrit
cell
dc
link
sens
environ
innat
immun
system
initi
adapt
immun
respons
accordingli
dc
consid
major
target
develop
immunomodul
compound
studi
effect
niclosamid
food
drug
administrationapprov
antihelminth
drug
activ
lipopolysaccharid
lp
stimul
murin
bone
marrowderiv
dc
examin
experiment
result
show
niclosamid
reduc
proinflammatori
cytokin
chemokin
express
lpsactiv
dc
addit
niclosamid
also
affect
express
mhc
costimulatori
molecul
influenc
abil
cell
take
antigen
therefor
mix
cell
cultur
compos
syngen
ovaspecif
cell
dc
niclosamidetr
dc
show
decreas
abil
stimul
cell
prolifer
ifnc
product
furthermor
intraven
inject
niclosamid
also
attenu
contact
hypersensit
ch
mice
sensit
block
lpsinduc
activ
mapkerk
jnk
nfjb
may
contribut
inhibitori
effect
niclosamid
dc
activ
collect
find
suggest
niclosamid
manipul
function
dc
result
provid
new
insight
immunopharmacolog
role
niclosamid
suggest
may
use
treatment
chronic
inflammatori
disord
dcmediat
autoimmun
diseas
dendrit
cell
dc
potent
antigen
present
cell
requir
initi
cell
respons
function
bridg
innat
adapt
immun
system
local
circul
within
distinct
compart
lymphoid
peripher
nonlymphoid
organ
differ
stage
matur
dc
normal
resid
immatur
state
within
peripher
nonlymphoid
tissu
serv
sentinel
incom
antigen
associ
microbi
pathogen
tumor
therefor
upon
antigen
captur
process
peripher
nonlymphoid
tissu
dc
migrat
affer
lymphat
vessel
secondari
lymphoid
organ
stimul
cell
undergo
morpholog
phenotyp
function
chang
characterist
matur
matur
dc
possess
immunostimulatori
properti
reduc
phagocyt
activ
increas
surfac
express
major
histocompat
complex
mhc
present
agpeptid
increas
express
costimulatori
molecul
increas
secret
cytokin
chemokin
contrast
enhanc
cell
immun
associ
matur
dc
immatur
dc
fail
stimul
cell
respons
involv
induct
peripher
cell
toler
gener
function
treg
cell
thu
potenti
har
power
dc
make
cell
attract
pharmacolog
target
http
recent
develop
indic
rediscoveri
inher
valu
fdaapprov
drug
grow
trend
pharmaceut
industri
repurpos
reposit
exist
drug
acceler
timelin
reduc
cost
bring
drug
market
elimin
need
addit
toxicolog
pharmacokinet
assess
niclosamid
food
drug
administrationapprov
oral
antihelminth
drug
use
treat
tapeworm
includ
beef
tapeworm
dwarf
tapeworm
use
human
nearli
year
also
use
molluscicid
water
treatment
schistosomiasi
control
program
activ
niclosamid
parasit
believ
due
inhibit
mitochondri
oxid
phosphoryl
anaerob
atp
product
howev
niclosamid
receiv
renew
attent
light
new
data
show
strong
antineoplast
activ
broad
spectrum
cancer
type
exampl
sever
report
indic
niclosamid
suppress
wntbcatenin
signal
target
wnt
coreceptor
cell
surfac
activ
close
associ
antiprolifer
proapoptot
activ
prostat
breast
cancer
cell
addit
jin
et
al
report
niclosamid
inhibit
pathway
increas
ro
level
acut
myelogen
leukemia
stem
cell
niclosamid
also
potent
inhibit
growth
aml
cell
vitro
nude
mice
studi
ren
et
al
demonstr
niclosamid
select
inhibitor
treatment
niclosamid
inhibit
egfmedi
activ
inhibit
growth
sever
type
cancer
cell
constitut
activ
eg
hela
moreov
use
autom
cellbas
screen
assay
balgi
et
al
observ
niclosamid
increas
autophagi
inhibit
mammalian
target
rapamycin
complex
signal
independ
fonseca
et
al
demonstr
niclosamid
suppress
signal
modul
cytoplasm
ph
breast
cancer
cell
furthermor
wang
et
al
report
niclosamid
potent
suppress
notchregul
gene
c
promoterbind
leukemia
cell
taken
togeth
data
suggest
antitumor
activ
niclosamid
may
due
abil
target
multipl
signal
pathway
howev
cellular
molecular
target
drug
immun
system
remain
unknown
abil
niclosamid
modul
function
dc
potent
apc
defin
initi
studi
design
experi
examin
potenti
therapeut
effect
niclosamid
function
properti
dc
elucid
molecular
mechan
involv
present
studi
demonstr
niclosamid
inhibit
abil
lpsinduc
mous
bone
marrowderiv
dc
secret
proinflammatori
cytokin
affect
express
costimulatori
molecul
abil
dc
prime
cell
immun
respons
syngen
dct
cell
cocultur
prevent
contact
hypersensit
ch
vivo
consequ
block
lpsinduc
nfjb
erk
jnk
activ
dc
may
explain
inhibitori
effect
niclosamid
dc
activ
result
show
first
time
niclosamid
manipul
immunostimulatori
properti
dc
may
use
suppress
chronic
inflammatori
disord
autoimmun
diseas
femal
b
mice
week
old
purchas
nation
laboratori
anim
center
taipei
taiwan
oti
tcr
transgen
mice
purchas
jackson
laboratori
bar
harbor
usa
otii
tcr
transgen
mice
provid
dr
clifford
lowel
ucsf
san
francisco
ca
mice
hous
barrier
facil
taichung
veteran
gener
hospit
taiwan
guidelin
institut
anim
care
use
committe
experi
conduct
accord
institut
guidelin
anim
experiment
mous
bone
marrowderiv
dc
gener
use
previous
describ
method
briefli
bone
marrow
cell
flush
femur
tibia
mice
rpmi
use
syring
needl
erythrocyt
lyse
red
blood
cell
lysi
buffer
bone
marrow
cell
suspend
medium
supplement
heatinactiv
fetal
bovin
serum
uml
penicillin
g
lgml
streptomycin
ngml
recombin
mous
granulocyt
macrophag
colonystimul
factor
peprotech
ngml
recombin
mous
place
plate
cell
incub
co
atmospher
fresh
cultur
medium
ad
cell
everi
day
day
nonadher
loos
adher
cell
harvest
classifi
immatur
dc
cell
express
determin
flow
cytometri
data
shown
dc
prepar
immunomagnet
select
enrich
bm
cell
posit
select
use
bead
miltenyi
biotec
auburn
ca
usa
accord
manufactur
instruct
cell
use
experi
puriti
cell
confirm
flow
cytometri
dc
cultur
presenc
dmso
lm
niclosamid
sigma
st
loui
mo
usa
stock
solut
mm
dmso
h
follow
stimul
ngml
lipopolysaccharid
lp
h
control
untreat
group
incub
dc
harvest
stain
specif
antibodi
mab
stain
sampl
analyz
fluoresc
facscalibur
flow
cytomet
bd
bioscienc
heidelberg
germani
use
fitcor
phycoerythrin
pe
conjug
monoclon
antibodi
mab
stain
mous
mhc
class
ii
class
express
bd
bioscienc
mountain
view
ca
cultur
supernat
collect
dc
propag
presenc
dmso
indic
dose
niclosamid
h
stimul
lp
ngml
tlr
ligand
includ
peptidoglycan
lgml
polyi
c
lgml
cpg
odn
nm
imiquimod
lgml
h
tnfalpha
h
tlr
ligand
purchas
invivogen
san
diego
ca
incub
cytokin
chemokin
level
supernat
dc
cultur
determin
use
sandwich
elisa
kit
r
system
minneapoli
mn
viabil
cultur
cell
assess
use
colorimetr
assay
kit
accord
manufactur
instruct
sigma
st
loui
mo
cell
viabil
greater
observ
experi
studi
protocol
assay
modifi
previou
report
bmdc
gener
incub
lg
ml
ova
ovap
ova
ovap
synthes
echo
chemic
co
taiwan
presenc
dmso
niclosamid
lm
h
subsequ
dc
stimul
lp
ngml
h
control
untreat
group
incub
cell
harvest
wash
pb
ovap
specif
cell
ovap
specif
cell
enrich
splenocyt
oti
otii
tcr
transgen
mice
mac
cell
separ
accord
manufactur
protocol
miltenyi
biotec
enrich
cell
cultur
stimul
dc
variou
dc
cell
ratio
h
prolifer
cell
estim
base
h
thymidin
uptak
addit
supernat
dct
cell
cultur
collect
h
level
ifngamma
product
measur
use
elisa
kit
proport
ifngamma
ifngamma
doubleposit
cell
measur
intracellular
cytokin
stain
use
facscalibur
flow
cytometri
bd
biosceinc
usa
previou
describ
total
cfse
lm
molecular
probe
stain
oti
otii
spleen
cell
inject
intraven
iv
syngen
recipi
mice
day
day
bmdc
mice
activ
lgml
ova
ovap
ova
ovap
h
peptideload
bmdc
iv
inject
mice
day
oti
otii
cell
prolifer
analyz
dilut
cfse
label
popul
use
flow
cytometri
endocytosi
dc
assess
dextranfitc
ovafitc
uptak
describ
previous
briefli
enrich
mous
bone
marrowderiv
dc
treat
niclosamid
lm
dmso
plu
lp
ngml
niclosamid
plu
lp
h
control
untreat
group
cell
harvest
incub
h
mgml
dextranfitc
molecular
weight
sigma
lgml
ovafitc
invitrogenmolecular
probe
uptak
dextranfitc
ovafitc
dc
analyz
use
facscalibur
flow
cytomet
addit
parallel
experi
perform
demonstr
uptak
dextran
dc
inhibit
low
temperatur
dc
cultur
presenc
dmso
niclosamid
lm
h
subsequ
stimul
lp
ng
ml
cell
harvest
whole
cell
lysat
prepar
min
lp
stimul
control
untreat
group
protein
detect
protein
extract
lgml
boil
electrophores
sdspolyacrylamid
gel
transfer
nitrocellulos
membran
membran
block
h
skim
milk
tb
tween
block
membran
incub
primari
antibodi
total
phospho
jnk
bactin
cell
signal
beverli
total
jnk
santa
cruz
biotechnolog
santa
cruz
ca
overnight
membran
wash
incub
horseradish
peroxidaselabel
secondari
ab
jackson
immunoresearch
west
grove
pa
protein
detect
use
western
lightn
chemiluminesc
reagent
perkin
elmer
life
scienc
boston
analyz
system
fujifilm
tokyo
japan
densitometr
analysi
perform
imagej
softwar
nation
institut
health
bethesda
md
usa
measur
nfjb
transcript
activ
purifi
bmdc
cellswel
stimul
dmso
niclosamid
lm
h
subsequ
stimul
lp
ngml
min
plate
cell
harvest
nuclear
extract
prepar
use
neper
nuclear
cytoplasm
extract
system
pierc
accord
manufactur
instruct
bca
protein
assay
kit
pierc
rockford
il
usa
use
determin
protein
concentr
assay
total
lg
nuclear
extract
use
transam
nfjb
elisa
kit
activ
motif
carlsbad
ca
accord
manufactur
instruct
dnfb
sigmaaldrich
induc
contact
hypersensit
ch
model
construct
use
previous
describ
method
modif
shave
belli
mice
paint
daili
vehicl
acetoneol
oil
ratio
wv
dnfb
plu
iv
daili
solvent
solut
cremophor
el
nacl
niclosamid
mgkg
five
day
sensit
dnfb
wv
paint
side
right
ear
mice
ch
respons
determin
h
exposur
dnfb
histolog
analysi
use
h
e
stain
evalu
increas
thick
ear
thick
right
challeng
ear
minu
thick
left
unchalleng
ear
use
engin
springload
micromet
mitutoyo
tokyo
japan
statist
analys
perform
use
graphpad
prism
softwar
packag
version
graphpad
softwar
san
diego
ca
usa
cytokin
product
cell
prolifer
vitro
vivo
ifngamma
product
immunoblot
assay
increas
thick
ear
evalu
oneway
anova
follow
tukey
post
hoc
test
p
differ
consid
statist
signific
major
attribut
matur
dc
synthesi
secret
cytokin
chemokin
modul
inflammatori
respons
cell
differenti
respons
adapt
immun
respons
therefor
first
seri
experi
investig
effect
niclosamid
product
proinflammatori
cytokin
chemokin
lpsstimul
matur
mous
bone
marrowderiv
dc
first
supernat
collect
lpsactiv
mous
dc
propag
presenc
absenc
niclosamid
cytokin
chemokin
level
supernat
quantifi
elisa
bacteri
lp
wide
use
strong
induc
dc
activ
shown
fig
dc
expos
niclosamid
exhibit
signific
dosedepend
decreas
level
lpsinduc
proinflammatori
cytokin
tnfalpha
chemokin
rant
alpha
addit
level
cytokin
chemokin
signific
differ
niclosamidetr
dmsotreat
dc
absenc
lp
moreov
decreas
cytokin
chemokin
level
due
increas
number
dead
cell
determin
mark
differ
cell
viabil
lm
niclosamidetr
cultur
dmsotreat
control
cultur
supplement
fig
thu
result
suggest
niclosamid
suppress
inflammatori
immunostimulatori
activ
dc
stimul
lp
activ
dc
accompani
enhanc
express
surfac
molecul
includ
costimulatori
molecul
major
histocompat
complex
molecul
mhc
mediat
interact
cell
contribut
cell
activ
thu
determin
whether
treatment
niclosamid
affect
express
surfac
molecul
mous
dc
shown
fig
niclosamid
treatment
significantli
alter
express
costimulatori
molecul
major
histocompat
complex
molecul
mhc
class
ii
mhc
class
fig
within
h
compar
lpsstimul
matur
dc
expos
niclosamid
thu
suggest
niclosamid
also
impair
lpsinduc
phenotyp
matur
dc
howev
also
import
note
immatur
dc
possess
stronger
endocyt
activ
matur
dc
therefor
examin
abil
niclosamidetr
dc
endocytos
dextranfitc
ovafitc
show
fig
b
percentag
dextranfitcand
ovafitc
posit
cell
signific
differ
niclosamidetr
dc
dmsotreat
dc
therefor
lower
percentag
lpsstimul
dc
dmsotreat
dc
endocyt
moreov
addit
pretreat
niclosamid
also
increas
endocyt
capac
lpsstimul
dc
dextranfitc
ovafitc
find
pertain
express
surfac
molecul
endocytot
activ
strongli
suggest
niclosamid
prevent
matur
dc
one
critic
function
activ
dc
induc
cell
prolifer
differenti
thu
next
studi
effect
niclosamid
abil
dc
induc
ovaspecif
cell
respons
ova
ovap
ova
ovap
peptideload
immatur
mous
dc
pretreat
presenc
absenc
niclosamid
stimul
lp
test
capac
stimul
allogen
ovaspecif
oti
otii
cell
cell
prolifer
measur
h
thymidin
incorpor
shown
fig
lpsactiv
dc
promot
cell
prolifer
effect
abrog
niclosamid
suggest
niclosamid
decreas
abil
lpstreat
dc
stimul
cell
also
evalu
effect
cell
cocultur
niclosamidetr
dc
ifngamma
cytokin
synthesi
shown
fig
c
cytokin
analysi
elisa
intracellular
cytokin
stain
reveal
cell
cocultur
niclosamidetr
dc
produc
significantli
lower
amount
ifnc
medium
fig
percentag
ifngamma
produc
cell
fig
dmsotreat
dc
presenc
lp
next
extend
vitro
result
obtain
prolifer
cell
vivo
model
cfselabel
spleen
cell
either
oti
otii
mice
iv
inject
syngen
mice
h
later
ova
ovap
ova
ovap
peptideload
immatur
mous
dc
pretreat
presenc
absenc
niclosamid
stimul
lp
administr
rout
three
day
dc
inject
prolifer
cell
evalu
spleen
recipi
mice
dilut
cfse
signal
shown
fig
prolifer
observ
mice
inject
lpsmatur
dc
howev
effect
attenu
niclosamid
overal
data
suggest
niclosamid
imped
abil
dc
prime
cellsbias
immun
respons
shown
previous
activ
mapk
nfjb
play
pivot
role
product
cytokin
dc
respons
inflammatori
stimuli
includ
lp
tnfalpha
ill
gain
insight
mechan
inhibitori
action
niclosamid
investig
whether
activ
mapk
nfjb
alter
niclosamid
lpsstimul
mous
dc
result
show
pretreat
niclosamid
attenu
lpsinduc
erk
jnkmapk
phosphoryl
affect
phosphoryl
fig
determin
whether
niclosamid
decreas
lpsinduc
activ
nfjb
pathway
nuclear
extract
prepar
nfjb
bind
activ
assess
use
transam
nfjb
transcript
factor
assay
kit
shown
fig
lp
induc
signific
level
nuclear
transloc
upregul
nfjb
bind
activ
min
stimul
howev
nfjb
bind
activ
dramat
reduc
niclosamidetr
bmdc
therefor
result
may
partial
explain
inhibitori
effect
niclosamid
matur
lpsinduc
dc
contact
hypersensit
ch
typic
dc
mediat
celldepend
agspecif
inflammatori
respons
induc
skin
expos
hapten
dnfb
model
use
investig
vivo
effect
niclosamid
dcmediat
immun
respons
result
show
iv
inject
niclosamid
mgkg
elicit
less
ear
swell
inject
vehicl
control
group
fig
suggest
niclosamid
could
potenti
use
prevent
delayedtyp
hypersensit
diseas
allerg
contact
dermat
niclosamid
food
drug
administrationapprov
antihelminth
agent
choic
treatment
tapeworm
infect
recent
shown
larg
spectrum
biolog
effect
includ
activ
sar
viru
antitoxin
antitumor
activ
variou
system
present
data
show
niclosamid
attenu
lpsinduc
proinflammatori
cytokin
chemokin
product
surfac
costimulatori
mhc
molecul
express
reduct
antigen
uptak
dc
inhibit
dctrigger
allogen
cell
prolifer
best
knowledg
first
studi
report
niclosamid
modul
phenotyp
function
properti
dc
tnfalpha
import
mediat
wide
rang
biolog
activ
play
numer
benefici
role
modul
proinflammatori
immun
respons
howev
dysregul
product
two
cytokin
dc
implic
pathogenesi
varieti
acut
chronic
inflammatori
diseas
well
autoimmun
diseas
rheumatoid
arthriti
ankylos
spondyl
psoriasi
refractori
asthma
therefor
small
molecul
inhibitor
monoclon
antibodi
target
cytokin
use
clinic
treatment
immunerel
diseas
exampl
multipl
monoclon
antibodi
tnf
includ
infliximab
adalimumab
certolizumab
pegol
use
therapeut
circul
receptor
fusion
protein
etanercept
enbrel
also
target
tnf
drug
tocilizumab
human
monoclon
antibodi
target
result
indic
niclosamid
strongli
inhibit
function
inflammatori
cytokin
tnfalpha
without
toxic
niclosamid
evalu
clinic
immunosuppress
therapi
adjuv
immunotherapi
drug
identifi
cytokin
strongli
influenc
differenti
cell
helper
cell
produc
ifngamma
aid
cellmedi
immun
present
studi
demonstr
niclosamid
significantli
reduc
lpsinduc
product
bmdc
also
regul
capac
lpsstimul
dc
induc
ifngamma
express
allogen
cell
fig
observ
suggest
niclosamid
may
effect
sever
chronic
inflammatori
diseas
describ
diseas
howev
exclud
possibl
niclosamid
may
modul
respons
type
lymphocyt
specif
ligand
lp
use
studi
stimul
dc
matur
lp
shown
induc
strong
respons
instead
immun
respons
data
indic
express
dc
lp
stimul
data
shown
therefor
util
agent
capabl
stimul
respons
dust
mite
allergen
determin
effect
niclosamid
dcmediat
polar
examin
futur
determin
mechan
niclosamid
inhibit
dc
function
examin
downstream
signal
pathway
nfjb
demonstr
regul
express
proinflammatori
mediat
includ
costimulatori
molecul
cytokin
adhes
molecul
dc
upregul
dc
matur
addit
experi
nfjb
subunit
knockout
mice
indic
crel
control
express
costimulatori
molecul
cytokin
cell
respons
induc
lipopolysaccharid
lp
stimul
dc
previou
studi
demonstr
tnfalphainduc
nfjb
activ
acut
myelogen
leukemia
stem
cell
significantli
suppress
niclosamid
present
studi
show
niclosamid
inhibit
nfjb
activ
lpstreat
dc
fig
suggest
inhibit
nfjb
activ
might
import
mechan
inhibit
dc
matur
niclosamid
addit
mitogenactiv
protein
kinas
mapk
pathway
cjun
ntermin
jnk
extracellular
signalregul
kinas
erk
direct
express
variou
gene
relat
dc
matur
play
major
role
dc
function
studi
also
observ
niclosamid
moder
decreas
erk
jnk
chang
activ
lpstreat
bmdc
suggest
niclosamid
inhibit
tlrrelat
signal
perhap
includ
nfjb
mapkerk
jnk
signal
pathway
howev
niclosamid
demonstr
regul
multipl
signal
pathway
pathway
involv
immun
respons
akt
thu
addit
studi
need
determin
whether
pathway
involv
effect
fulli
elucid
signal
pathway
respons
inhibit
dc
matur
niclosamid
worth
note
although
current
studi
demonstr
first
time
niclosamid
inhibit
lpsinduc
mapkerk
signal
pathway
bmdc
recent
report
niclosamid
dose
affect
induct
mekerk
mnk
pathway
serum
starvat
cell
preliminari
infer
suggest
least
two
possibl
caus
differ
result
first
differ
effect
erk
activ
niclosamid
may
due
speciesspecif
celltyp
differ
second
niclosamid
may
directli
target
erk
may
instead
regul
pathway
upstream
erk
thu
niclosamid
differ
effect
erk
activ
serumstarv
cell
lpstreat
bmdc
howev
identif
possibl
mechan
respons
differ
effect
may
lead
futur
applic
niclosamid
treatment
clinic
diseas
separ
studi
found
niclosamid
abl
repress
express
proinflammatori
cytokin
regardless
whether
administ
lp
stimul
level
mapk
phosphoryl
examin
western
blot
analysi
antibodi
erk
jnk
mapk
phosphoryl
unphosphoryl
band
analyz
imagej
normal
actin
b
nfjb
assay
perform
describ
materi
method
od
measur
nm
data
shown
mean
sd
sampl
three
well
ns
p
p
p
indic
signific
differ
niclosamidetr
dmsotreat
lpsactiv
dc
data
repres
three
independ
experi
similar
result
supplement
fig
suggest
antiinflammatori
immunomodulatori
effect
niclosamid
could
clinic
effect
prevent
treatment
variou
diseas
addit
also
test
whether
niclosamid
could
modul
activ
immatur
dc
tlr
ligand
name
peptidoglycan
polyi
c
cpg
odn
imiquimod
tlr
ligand
increas
releas
proinflammatori
cultur
medium
releas
reduc
treatment
lm
niclosamid
supplement
fig
although
mechan
niclosamid
interfer
dc
activ
upon
stimul
differ
tlr
ligand
larg
unknown
suggest
may
relat
effect
niclosamid
via
suppress
mapk
nfjb
signal
pathway
pathway
nfjb
believ
play
import
role
variou
tlr
ligandstimul
select
cytokin
chemokin
secret
dendrit
cell
previou
studi
show
niclosamid
low
toxic
mammal
oral
rat
mgkg
addit
singl
oral
administr
mgkg
niclosamid
gener
maxim
plasma
concentr
lm
rat
anoth
possibl
achiev
higher
plasma
concentr
drug
may
intraven
administr
instanc
singl
intraven
administr
mgkg
niclosamid
rat
gave
rise
peak
plasma
concentr
lm
suffici
modul
dc
function
extrapol
data
dendrit
cell
activ
use
tlr
ligand
proinflamtori
cytokin
shift
metabol
oxid
phosphoryl
aerob
glycolysi
ie
warburg
effect
krawczyk
et
al
describ
phenomenon
dc
also
demonstr
tlr
stimul
essenti
dendrit
cell
matur
consequ
accord
previou
studi
uncoupl
mitochondri
oxid
phosphoryl
also
believ
antihelminth
mechan
action
thu
hypothes
immunomodulatori
effect
niclosamid
dendrit
cell
could
part
due
disrupt
metabol
niclosamid
fda
approv
human
use
parasit
helminth
infest
decad
recent
year
niclosamid
shown
antivir
effect
exampl
jurgeit
et
al
found
niclosamid
entri
inhibitor
number
phdepend
respiratori
virus
includ
influenza
viru
human
rhinovirus
imperi
et
al
show
micromolar
concentr
niclosamid
high
inhibitori
activ
pseudomona
aeruginosa
qs
virul
vitro
vivo
moreov
wu
et
al
demonstr
niclosamid
abl
inhibit
replic
sarscov
viral
antigen
synthesi
total
abolish
niclosamid
concentr
lm
suggest
drug
possibl
candid
treatment
sarscov
infect
first
studi
demonstr
abil
niclosamid
modul
activ
immatur
dc
sever
type
tlr
ligand
sinc
dc
crucial
elimin
pathogen
tumor
studi
also
examin
risk
associ
longterm
niclosamid
use
summari
result
demonstr
first
time
fdaapprov
drug
niclosamid
inhibit
lpsinduc
dc
matur
cytokin
costimulatori
molecul
mhc
molecul
express
addit
niclosamidetr
dc
inhibit
antigen
specif
cell
respons
prompt
us
specul
might
import
function
niclosamid
howev
also
believ
addit
issu
warrant
futur
investig
includ
molecular
mechan
underli
abil
niclosamid
suppress
dc
function
increas
ear
thick
measur
h
data
shown
mean
sd
six
mice
repres
two
independ
experi
yield
similar
result
p
indic
signific
differ
dnfb
solvent
iv
dnfb
niclosamid
b
repres
histopatholog
ear
tissu
cryosect
ear
differ
treat
mice
prepar
h
hapten
challeng
stain
hematoxylin
eosin
h
e
origin
magnif
